Intellia Therapeutics (NTLA) said Sunday that 10 patients with hereditary angioedema patients in a phase 1/2 study were attack-free and treatment-free for a median of nearly two years after a single dose of its Crispr-based potential therapy lonvoguran ziclumeran.

The genetic disease recurrent swelling and possible abdominal pain.

With up to three years of follow-up, patients in the study experienced a mean reduction of monthly attacks of 98% after the single dose, the company said.

A phase 3, randomized, double-blind, placebo-controlled trial is ongoing, the company said.

Intellia also said it expects to submit a biologics license application in 2026 to support its plans for a US launch in 2027.